Literature DB >> 7726505

Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus.

B Fantin1, R Leclercq, Y Merlé, L Saint-Julien, C Veyrat, J Duval, C Carbon.   

Abstract

In order to determine the microbiological and pharmacokinetic parameters that best predicted the in vivo antistaphylococcal activity of the streptogramin RP 59500 (quinupristin-dalfopristin), we evaluated the activity in rabbit aortic endocarditis of three regimens of quinupristin-dalfopristin against five strains of Staphylococcus aureus with various streptogramin B-type antibiotic resistance phenotypes and susceptible to streptogramin A-type antibiotics. Quinupristin-dalfopristin was as active as vancomycin against three strains that were susceptible to its streptogramin B component quinupristin, including one strain that was inducibly resistant to erythromycin, but had a significantly decreased activity against two strains that were resistant to quinupristin, for all quinupristin-dalfopristin regimens tested (P < 0.05). The area under the concentration-time curve for quinupristin-dalfopristin in plasma divided by the MIC of quinupristin was the only parameter retained by multilinear regression that predicted the in vivo activity of quinupristin-dalfopristin (P = 0.0001), emphasizing the importance of determining the susceptibility to quinupristin in order to predict the in vivo activity of quinupristin-dalfopristin against S. aureus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7726505      PMCID: PMC162550          DOI: 10.1128/AAC.39.2.400

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Peritonitis due to vancomycin-resistant Staphylococcus epidermidis.

Authors:  D Sanyal; A P Johnson; R C George; B D Cookson; A J Williams
Journal:  Lancet       Date:  1991-01-05       Impact factor: 79.321

Review 2.  Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification.

Authors:  R Leclercq; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

3.  World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus.

Authors:  P A Maple; J M Hamilton-Miller; W Brumfitt
Journal:  Lancet       Date:  1989-03-11       Impact factor: 79.321

4.  Conjugative transfer of staphylococcal antibiotic resistance markers in the absence of detectable plasmid DNA.

Authors:  N el Solh; J Allignet; R Bismuth; B Buret; J M Fouace
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

5.  Discrepancies between MBC and actual killing of viridans group streptococci by cell-wall-active antibiotics.

Authors:  P R Meylan; P Francioli; M P Glauser
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

Review 6.  Inducible resistance to macrolides, lincosamides and streptogramin type B antibiotics: the resistance phenotype, its biological diversity, and structural elements that regulate expression--a review.

Authors:  B Weisblum
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

7.  In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis.

Authors:  B Fantin; R Leclercq; M Ottaviani; J M Vallois; B Maziere; J Duval; J J Pocidalo; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

8.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

9.  Analysis of pristinamycin-resistant Staphylococcus epidermidis isolates responsible for an outbreak in a Parisian hospital.

Authors:  V Loncle; A Casetta; A Buu-Hoi; N el Solh
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

10.  Microdilution transfer plate technique for determining in vitro synergy of antimicrobial agents.

Authors:  P F Dougherty; D W Yotter; T R Matthews
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

View more
  30 in total

1.  Diminished killing of pneumococci by pristinamycin demonstrated by time-kill studies.

Authors:  L Schlegel; G Sissia; A Frémaux; P Geslin
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 3.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

4.  Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models.

Authors:  D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

5.  Agents for the Treatment of Multidrug-resistant Gram-positive Endocarditis.

Authors:  Jennifer K Long
Journal:  Curr Infect Dis Rep       Date:  2005-07       Impact factor: 3.725

Review 6.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

7.  Influence of resistance to streptogramin A type antibiotics on the activity of quinupristin-dalfopristin in vitro and in experimental endocarditis due to Staphylococcus aureus.

Authors:  V Zarrouk; B Bozdogan; R Leclercq; L Garry; C Carbon; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

8.  Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.

Authors:  M W Climo; R L Patron; B P Goldstein; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 9.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

Review 10.  Clinical pharmacokinetics of quinupristin/dalfopristin.

Authors:  David T Bearden
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.